FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
NEW YORK, April 05, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Cardiovascular Systems, Inc. (“Cardiovascular Systems”) (NASDAQ:CSII) between September 12, 2011 and January 21, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired Cardiovascular Systems securities between September 12, 2011 and January 21, 2016, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/cardiovascular-systems.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cardiovascular-systems.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
